Q2055 Insurance Policy Changes

HCPCS Q2055 is officially defined as "Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose." HCPCS Q2055 is referenced in 3 tracked payer policy changes from Humana and CareSource. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q2055 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Related

All billing codesJ35909921399212992029921499203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert